Sharp Supports Development of COVID-19 Vaccines and Treatments

Sharp Clinical, a provider of global clinical supply services, has confirmed that it is involved in supporting six clinical trials related to COVID-19.
 
The company is currently delivering clinical trial packaging, labeling and distribution services for two biotech organizations that are developing potential vaccines for the virus.
 
Sharp is also delivering a combination of services to support multiple hydroxychloroquine projects, including placebo manufacturing, packaging, labeling, distribution and comparator sourcing, as clinical trials have launched globally to assess the drugs suitability to treat COVID-19 symptoms.
 
"We are very proud of the work we do every day in support of our pharma clients, but never more so than today as we actively support our clients’ clinical studies related to COVID-19," said Frank Lis, president, Sharp Clinical. "In the face of this global pandemic, the clinical trials industry continues to focus its attention on the discovery and development of potential vaccines and treatments for COVID-19 and Sharp Clinical is playing its part."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.